HAXBY GROUP SCARBOROUGH
LAWRENCE HOUSE MED CTR, 1A BELGRAVE CRESCENT, SCARBOROUGH
HF 4
The percentage of patients with a current diagnosis of heart failure due to LVD who are currently treated with an ACE inhibitor or Angiotensin Receptor Blocker, who are additionally treated with a beta-blocker licensed for heart failure, or recorded as intolerant to or having a contraindication to beta-blockers.
| Indicator | Year | Numerator | Denominator | Ratio | Centile |
|---|---|---|---|---|---|
| HF 4 | 2010 | 37 | 60 | 61.7% | |
| HF 4 | 2011 | 44 | 61 | 72.1% | |
| HF 4 | 2012 | 54 | 68 | 79.4% | |
| HF 4 | 2013 | 64 | 71 | 90.1% | |
| HF004 | 2014 | 67 | 75 | 89.3% | |
| HF004 | 2015 | 63 | 69 | 91.3% | |
| HF004 | 2016 | 58 | 65 | 89.2% | |
| HF004 | 2017 | 54 | 57 | 94.7% | |
| HF004 | 2018 | 53 | 56 | 94.6% | |
| HF004 | 2019 | 118 | 144 | 81.9% | |
| HF004 | 2020 | 101 | 122 | 82.8% | |
| HF006 | 2021 | 104 | 137 | 75.9% | |
| HF006 | 2022 | 118 | 120 | 98.3% | |
| HF006 | 2023 | 119 | 122 | 97.5% |
